Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 11Lymphoma, Mantle-Cell 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Non-Hodgkin 5Lymphoma 3Waldenstrom Macroglobulinemia 2Neoplasms 2Burkitt Lymphoma 2Bronchiolitis Obliterans Syndrome 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Leukemia, B-Cell 1Leukemia 1Hematologic Diseases 1Head and Neck Neoplasms 1Anemia 1

Interventions

fludarabine 10Specimen Handling 8Cytarabine 8Cyclophosphamide 8Biopsy 8fludarabine phosphate 7Whole-Body Irradiation 7venetoclax 6Injections 6Busulfan 6Azacitidine 6Mycophenolic Acid 5Melphalan 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5decitabine and cedazuridine drug combination 4X-Rays 4Tacrolimus 4Stem Cell Transplantation 4Cyclosporine 4CPX-351 4Peripheral Blood Stem Cell Transplantation 3Magnetic Resonance Spectroscopy 3Idarubicin 3Decitabine 3treosulfan 2ruxolitinib 2luspatercept 2ivosidenib 2gilteritinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × ibrutinib × 30 days × Clear all
NCT06788509 2026-06-05

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Janssen Research & Development, LLC

Phase 1 Enrolling by invitation
120 enrolled
GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡